Hunan Er-Kang Pharmaceutical Co., Ltd

300267

CNE100001781

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-15 EDT			5-day change	1st Jan Change
2.61 ^CNY	0.00%		-7.12%	-18.69%

04-26	Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes

November 15, 2022 at 02:33 pm

Hunan Er-Kang Pharmaceutical Co. Ltd. at its EGM held on 14 November 2022 appointed Sun Qingrong as non-independent directors. Tan Xue appointed as independent directors.

Li Haiyi appointed as non-employee supervisors.

Latest news about Hunan Er-Kang Pharmaceutical Co., Ltd

Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-22	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2022 Final Profit Distribution, Payable on 09 June 2023	23-06-02	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan	23-05-19	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2022	23-04-27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
ER-KANG Pharma Earmarks $140 Million for Lithium Carbonate Factory; Shares Gain 7%	22-11-16	MT
Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes	22-11-15	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces Profit Distribution Proposal for 2021	22-04-28	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd signed equity purchase agreement to acquire Henan Yuxingkang Pharmaceutical Co., Ltd. from Shuai Fangwen and Cao Zaiyun for CNY 44 million.	21-10-27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Hunan Er-Kang Pharmaceutical Co., Ltd(XSEC:300267) added to S&P Global BMI Index	21-09-20	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-26	CI
Xu Zhiqi completed the acquisition of 3.4% stake in Hunan Er-Kang Pharmaceutical Co., Ltd from Hunan Shuaijia Investment Co., Ltd.	21-07-20	CI
An unknown buyer agreed to acquire 3.4% stake in Hunan Er-Kang Pharmaceutical Co., Ltd for approximately CNY 200 million.	21-07-01	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09, June 2021	21-06-02	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Approves Final Cash Dividend for the Year 2020	21-05-21	CI
Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2020	21-04-28	CI

Chart Hunan Er-Kang Pharmaceutical Co., Ltd

Duration

Period

Chart Hunan Er-Kang Pharmaceutical Co., Ltd

More charts

HUNAN ER-KANG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and sales of pharmaceutical excipients, finished drugs and bulk drugs. The Companyâs pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

02:30am - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD	-18.69%	745M
ELI LILLY AND COMPANY	+32.36%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.60%	367B
MERCK & CO., INC.	+20.07%	334B
ABBVIE INC.	+6.04%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.27%	171B

Other Pharmaceuticals